Next-generation microbiome medicine may revolutionize the treatment of Parkinson’s and similar disorders
Scientists have engineered the probiotic bacterium Escherichia coli Nissle 1917 as a drug-delivery system that continuously produces and delivers the gold-standard Parkinson’s drug Levodopa, which is converted to dopamine in the brain. E. coli Nissle strain was chosen for its century-long record of safely treating gastrointestinal disorders in humans.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.